Blog
Archives: FAQs
-
How does the MPEP address the prima facie case of obviousness for ranges?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the MPEP define a “patent” for prior art purposes under 35 U.S.C. 102?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the MPEP address “or the like” phrases in patent claims?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the MPEP’s stance on using “optionally” in patent claims?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does MPEP treat optimization of ranges through routine experimentation?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the MPEP address the omission of a limitation in a patent claim?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does MPEP address the obviousness of similar proportions or amounts?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the definition of “nucleotide” according to the MPEP?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What types of backbone moieties are included in the MPEP’s definition of a nucleotide?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the MPEP address nucleotide analogs in its definition?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.